Drug intelligence / Profile preview

RBT-2

Development stage: Preclinical
Lead developer: Renibus Therapeutics
Modality: Small Molecules
Administration: Unknown

Overview

**RBT-2** is a small molecule drug under development by Renibus Therapeutics. It functions as an antioxidant and anti-fibrotic agent and has demonstrated the ability to reduce the progression risk of chronic kidney disease (CKD) in preclinical models. The mechanism of action is primarily through stimulation of ENHO (energy homeostasis associated protein), targeting pathways linked to energy homeostasis, oxidative stress, and fibrosis. RBT-2 is currently in the preclinical stage of development for chronic kidney disease[1][3][9][10][13].

Brand names: RBT-2RBT2RBT 2
Other names: RBT-2RBT2RBT 2

Targets

ENHO (Adropin)

Beyond the preview

Go deeper on RBT-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RBT-2.

Explore the full profile